Medtronic plc, a leader in healthcare technology, has announced a significant regulatory milestone for its Hugo™ robotic-assisted surgery $(RAS.AU)$ system. The company has secured the CE Mark for its LigaSure™ RAS vessel-sealing technology, enhancing the capabilities of the Hugo™ RAS system for gynecologic, general, and urologic procedures in Europe. This development marks the integration of Medtronic's trusted vessel-sealing technology onto the Hugo™ system, which has been utilized in over 35 million procedures globally. Additionally, in the U.S., the Hugo™ RAS system is under an ongoing regulatory review by the Food and Drug Administration for a urology indication, with potential market entry anticipated later this fiscal year. The system is currently in use across 30+ countries, further solidifying its growing momentum in the surgical field.